NO20083065L - Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstander - Google Patents
Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstanderInfo
- Publication number
- NO20083065L NO20083065L NO20083065A NO20083065A NO20083065L NO 20083065 L NO20083065 L NO 20083065L NO 20083065 A NO20083065 A NO 20083065A NO 20083065 A NO20083065 A NO 20083065A NO 20083065 L NO20083065 L NO 20083065L
- Authority
- NO
- Norway
- Prior art keywords
- sulfamoylpiperidinamides
- prophylaxis
- obesity
- treatment
- new
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- CWSZFZSSSFNENO-UHFFFAOYSA-N n-sulfamoylpiperidine-1-carboxamide Chemical class NS(=O)(=O)NC(=O)N1CCCCC1 CWSZFZSSSFNENO-UHFFFAOYSA-N 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05111882 | 2005-12-09 | ||
| PCT/EP2006/069482 WO2007065948A1 (en) | 2005-12-09 | 2006-12-08 | Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20083065L true NO20083065L (no) | 2008-09-04 |
Family
ID=36222433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083065A NO20083065L (no) | 2005-12-09 | 2008-07-08 | Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstander |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1960359A1 (pt) |
| JP (1) | JP2009518366A (pt) |
| KR (1) | KR20080074217A (pt) |
| CN (1) | CN101326166A (pt) |
| AU (1) | AU2006323952A1 (pt) |
| BR (1) | BRPI0619583A2 (pt) |
| CA (1) | CA2632719A1 (pt) |
| IL (1) | IL192025A0 (pt) |
| NO (1) | NO20083065L (pt) |
| RU (1) | RU2442773C2 (pt) |
| WO (1) | WO2007065948A1 (pt) |
| ZA (1) | ZA200804077B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627221T3 (es) | 2006-12-28 | 2017-07-27 | Rigel Pharmaceuticals, Inc. | Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso |
| ES2660170T3 (es) * | 2007-01-25 | 2018-03-21 | NAIA Metabolic, Inc. | Sensibilizadores a la insulina y métodos de tratamiento |
| CN102427810A (zh) * | 2009-05-01 | 2012-04-25 | 拉夸里亚创药株式会社 | 作为trpm8拮抗剂的氨磺酰基苯甲酸衍生物 |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN106546740B (zh) * | 2016-10-27 | 2019-04-09 | 暨南大学 | Ca2在鼻咽癌中的检测、治疗的应用 |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL357678A1 (en) * | 2000-04-28 | 2004-07-26 | Sankyo Company, Limited | Ppargamma modulators |
| US6946476B2 (en) * | 2000-12-21 | 2005-09-20 | Schering Corporation | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
-
2006
- 2006-12-08 WO PCT/EP2006/069482 patent/WO2007065948A1/en not_active Ceased
- 2006-12-08 EP EP06830478A patent/EP1960359A1/en not_active Withdrawn
- 2006-12-08 AU AU2006323952A patent/AU2006323952A1/en not_active Abandoned
- 2006-12-08 CN CNA2006800459849A patent/CN101326166A/zh active Pending
- 2006-12-08 KR KR1020087016422A patent/KR20080074217A/ko not_active Withdrawn
- 2006-12-08 BR BRPI0619583-0A patent/BRPI0619583A2/pt not_active IP Right Cessation
- 2006-12-08 RU RU2008127442/04A patent/RU2442773C2/ru not_active IP Right Cessation
- 2006-12-08 JP JP2008543846A patent/JP2009518366A/ja not_active Withdrawn
- 2006-12-08 ZA ZA200804077A patent/ZA200804077B/xx unknown
- 2006-12-08 CA CA002632719A patent/CA2632719A1/en not_active Abandoned
-
2008
- 2008-06-10 IL IL192025A patent/IL192025A0/en unknown
- 2008-07-08 NO NO20083065A patent/NO20083065L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2632719A1 (en) | 2007-06-14 |
| IL192025A0 (en) | 2008-12-29 |
| WO2007065948A1 (en) | 2007-06-14 |
| EP1960359A1 (en) | 2008-08-27 |
| BRPI0619583A2 (pt) | 2011-10-04 |
| AU2006323952A1 (en) | 2007-06-14 |
| ZA200804077B (en) | 2009-10-28 |
| JP2009518366A (ja) | 2009-05-07 |
| CN101326166A (zh) | 2008-12-17 |
| KR20080074217A (ko) | 2008-08-12 |
| RU2008127442A (ru) | 2010-01-20 |
| RU2442773C2 (ru) | 2012-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074275L (no) | 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister | |
| NO20081454L (no) | Met-kinaseinhibitorer | |
| NO20082090L (no) | Pyridopyrimidinoninhibitorer av P13K alfa | |
| NO20073849L (no) | Indolderivater for behandling av virale infeksjoner | |
| NO20063449L (no) | Substituerte heterocykler og deres anvendelse | |
| NO20091553L (no) | Fenylderivater og deres anvendelse som immunmodulatorer | |
| NO20070487L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
| NO20082509L (no) | Pyridopyrazinderivater og deres anvendelse | |
| NO20092053L (no) | HCV NS3-proteaseinhibitorer | |
| NO20076648L (no) | Novel thiophene derivatives | |
| NO20081729L (no) | Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer | |
| NO20070489L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
| NO20074634L (no) | Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer | |
| NO20090755L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
| NO20090628L (no) | Pyridizinon derivativater | |
| NO20083214L (no) | Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer | |
| NO20071504L (no) | Pyrimidinderivanter. | |
| NO20081217L (no) | Nye benzotiazolonderivater | |
| NO20075082L (no) | Pyridin-3-karboksamidderivater som CB1-inversagonister | |
| NO20080879L (no) | HCV-NS3-proteaseinhibitorer | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| NO20070081L (no) | Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer | |
| NO20080981L (no) | Nitrocatechol-derivater som COMT-inhibitorer | |
| NO20091326L (no) | Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |